Hence, it seems that [18F]Fluciclovine PET/CT has no significant role in the primary staging of PCa, and will be replaced by new PSMA targeting agents for biochemical recurrence in guidelines. This evidence concerns the gene FOLH1 and posterior cortical atrophy.